Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Lung Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 159Carboplatin 147Cisplatin 130Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 69Docetaxel 62Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33Radiosurgery 26130-nm albumin-bound paclitaxel 26fludarabine 23Ipilimumab 23Radiation 21Magnetic Resonance Spectroscopy 21Irinotecan 21Taxes 20Oxaliplatin 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × saracatinib × Thoracic × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT01000896 2010-02-04

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

AstraZeneca

Phase 1 Withdrawn
27 enrolled
GynecologicThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡